Icon plc Stock
€152.80
Your prediction
Icon plc Stock
Pros and Cons of Icon plc in the next few years
Pros
Cons
Performance of Icon plc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Icon plc | 1.320% | 3.488% | 6.296% | -47.509% | -25.645% | -27.238% | - |
Alkermes plc | -0.790% | -0.813% | 7.018% | -4.688% | -12.857% | -1.114% | 78.102% |
Ironwood Pharmaceuticals | 0.000% | 5.714% | 66.917% | -75.223% | -73.571% | -89.803% | -86.545% |
Novocure Ltd | 1.150% | 3.100% | 6.997% | -41.284% | -64.028% | -86.751% | -85.370% |
Comments
News

3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals

LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million

ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the